---
title: "Pharscin Pharma: Received the drug re-registration approval notice"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249361780.md"
description: "Pharscin Pharma recently received three \"Drug Re-registration Approval Notices\" issued by the Chongqing Municipal Drug Administration. The approved drugs include Ganju Bingmei Tablets, Liuwei Anshen Capsules, and Silotazol Tablets, which are used to treat voice loss and hoarseness caused by wind-heat invading the lungs, insomnia, and to improve ischemic symptoms caused by chronic arterial occlusion"
datetime: "2025-07-21T08:48:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249361780.md)
  - [en](https://longbridge.com/en/news/249361780.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249361780.md)
generator: "portal-rs"
---

# Pharscin Pharma: Received the drug re-registration approval notice

Pharscin Pharma announced that the company recently received the "Drug Re-registration Approval Notice" issued by the Chongqing Municipal Drug Administration for three of its drugs. The drugs included in the re-registration approval notice are Ganju Bingmei Tablets, Liuwei Anshen Capsules, and Silotazol Tablets. Ganju Bingmei Tablets are used for loss of voice and acute pharyngitis caused by wind-heat invading the lungs, Liuwei Anshen Capsules are used for insomnia classified as Yin deficiency with excessive fire and phlegm according to traditional Chinese medicine, and Silotazol Tablets are used to improve ischemic symptoms such as ulcers, limb pain, cold sensation, and intermittent claudication caused by chronic arterial occlusive disease, as well as to prevent the recurrence of cerebral infarction

### Related Stocks

- [002907.CN](https://longbridge.com/en/quote/002907.CN.md)

## Related News & Research

- [New Data Highlights Chianti Classico's Commitment to Sustainability](https://longbridge.com/en/news/298649206.md)
- [Hyrox founders reclaim majority stake in fitness-racing group with L Catterton-led investors](https://longbridge.com/en/news/298426349.md)
- [How Audi shortened development time for the A2 e-tron](https://longbridge.com/en/news/298718383.md)
- [Handa Oncology Receives FDA Final Approval for OMCAZIO(TM) (cabozantinib) Capsules](https://longbridge.com/en/news/298728074.md)
- [USFCR Recognized as Federal Contracting Services of the Year 2026 by Gov Business Review](https://longbridge.com/en/news/298637421.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**